Minims (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride, the active ingredient in Minims, is a local anesthetic presented as an ophthalmic solution for ocular use. It provides topical anesthesia of the eye surface for diagnostic procedures and minor surgeries.

GNH USA supplies Minims as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Oxybuprocaine Hydrochloride is a topical ocular anesthetic used to temporarily numb the surface of the eye.

- Diagnostic ocular examinations: provides anesthesia for slit‑lamp biomicroscopy, tonometry, and fluorescein staining. - Minor ocular surgery: facilitates procedures such as foreign body removal or superficial corneal surgery. - Laser procedures: enables patient comfort during laser photocoagulation or refractive laser treatments.

Adverse reactions may occur following ocular administration of oxybuprocaine.

Common Side Effects: - Burning or stinging sensation at the application site. - Transient redness or conjunctival hyperemia. - Excessive tearing or lacrimation. - Temporary blurred vision. - Mild allergic conjunctivitis. - Mild corneal epithelial irritation.

Serious or Rare Side Effects: - Corneal epithelial toxicity or ulceration. - Severe allergic reaction, including anaphylaxis. - Persistent increase in intra‑ocular pressure. - Vision loss or significant visual impairment. - Endophthalmitis. - Systemic toxicity with high systemic absorption.

When using Minims, consider the following precautions.

- Allergy assessment: avoid use in patients with known hypersensitivity to oxybuprocaine or other ester‑type anesthetics. - Contact lens wear: remove lenses before administration to prevent drug retention and irritation. - Corneal disease: use with caution in patients with epithelial defects, keratitis, or other corneal pathology. - Systemic absorption: limit repeated dosing to reduce risk of systemic toxicity. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at room temperature: keep in the original container, protect from light and moisture.

Potential drug interactions should be reviewed before administration.

Major Interactions (Avoid): - Systemic vasoconstrictors: may increase cardiovascular risk if absorbed systemically. - Other ocular anesthetics: additive local toxicity. - Anticholinergic eye drops: may reduce clearance of oxybuprocaine.

Moderate Interactions (Monitor Closely): - Topical antibiotics: monitor for delayed corneal healing. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Preservative‑containing eye solutions: watch for cumulative preservative toxicity.